Turla, A.
Laganà, M.
Cremaschi, V.
Zamparini, M.
De Maria, L.
Consoli, F.
Abate, A.
Tamburello, M.
Alberti, A.
Sigala, S.
Grisanti, S.
Fontanella, M. M.
Cosentini, D.
Berruti, A. http://orcid.org/0000-0002-3956-0043
Funding for this research was provided by:
CreativeLab ASD, Livorno, Italy
FIRM Onlus, Cremona, Italy
Università degli Studi di Brescia
Article History
Received: 2 February 2023
Accepted: 15 June 2023
First Online: 24 June 2023
Declarations
:
: Alfredo Berruti received fees for public speech from HRA Pharma and received research funds for research in adrenocortical carcinoma by Janssen and Sanofi. Sandra Sigala received funds for preclinical research in adrenocortical carcinoma from Novartis and Pharmamar. The other authors have no conflicts of interest to declare.
: The four adult patients followed at Spedali Civili of Brescia were included in the ENSAT registry (ExternalRef removed), approved by the Ethical Review Board of ASST-Spedali Civili in Brescia, and were treated in accordance with the Declaration of Helsinki.
: Written consent was obtained from each patient for the recording of pseudonymized and standardized data, including images, in the ENSAT registry for use in any current and future adrenal tumor-related projects.
: All the procedures being performed were part of the routine care.